Skip to main content
Premium Trial:

Request an Annual Quote

Gilbert Omenn, David Champagne, Jo Webber, Rebecca Caffrey, Stefan Muellner, Helmut Meyer, Gregory Kellog

Premium

Gilbert Omenn has been appointed to the board of directors of Ontario-based health care company OccuLogix. Omenn is a professor of internal medicine, human genetics and public health at the University of Michigan, and the leader of the Human Proteome Organization's Plasma Proteome Project.


Thermo Electron announced this week that it has appointed David Champagne as vice president and general manager of its informatics business. Champagne succeeds Jo Webber, who recently left the company to pursue a long-held desire to return to Europe and to spend time sailing the Mediterranean.

Champagne joined Thermo in April 2003 as director of global services for informatics, and was later promoted to divisional commercial director. Prior to joining Thermo, Champagne was president and CEO of ProActivity Software, and early-stage software company that provides business process analysis solutions. Before that, he was president and CEO of Upspring Software, a development tools vendor that was later acquired by MKS. Champagne also worked at Lotus Development, where he led a global support and service organization of over 1,200 service professionals.

Champagne obtained a BS in industrial engineering from the University of Massachusetts, and an MBA from Bryant University.


Rebecca Caffrey has become business development manager of tissue provider Asterand, the Detroit, Mich.-based company said this week. She joins the company from Ciphergen Biosystems, where she was a business development and product manager.


Stefan Muellner has become chief financial officer of Protagen, replacing Helmut Meyer, who will focus on his academic appointment, the German proteomics company said last week. Previously, he held R&D management positions at Henkel and Hoechst. Meyer, a professor at the Ruhr-University Bochum and chair of the human brain proteome initiative of the Human Proteome Organization, will join the company's board of directors, replacing Achim Riemann, who will leave the board.


Gregory Kellog has become chief technology officer of Protiveris, the Rockville, Md.-based company said this week. He is the former vice president of research at Network Biosystems where he helped develop a microfabrication-based electrophoresis system for forensic applications. Kellogg holds a PhD in physics from Harvard University.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.